When was Cerium founded?

Cerium was founded in 2012 and raised its 1st funding round 4 years after it was founded.

Where is Cerium located?

Cerium is headquartered in Gaithersburg, United States.

Who is the current CEO of Cerium?

Gregg Lapointe of Cerium. They have also founded 1 company.

How many employees does Cerium have?

As of Sep 30, 2026, the latest employee count at Cerium is 5.

Is Cerium a funded company?

Cerium is a funded company, having raised a total of $11.9M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 27, 2016.

When was the latest funding round of Cerium?

Cerium's latest funding was a $***** Series A round on May 22, 2026, with participation from 0 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $1.39B in funding in 2026 to date.

Where does Cerium rank among its competitors?

Cerium ranks 5th amongst 29 active competitors, of which 2 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Cerium, which secured $750K in May, 2026.

Who are the top competitors of Cerium?

Cerium's top competitors include Zenas BioPharma, CTI Clinical Trial and AllStripes. Among them, Cerium secured the most recent funding round in May, 2026.

Cerium - 2026 Company Profile, Team, Funding & Competitors

Cerium is a series A company based in Gaithersburg (United States), founded in 2012 by Gregg Lapointe. It operates as a CRO focusing on developing and commercialising of drugs for the treatment of orphan diseases. Cerium has raised $11.9M in funding. The company has 29 active competitors, including 2 funded and 4 that have exited. Its top competitors include companies like Zenas BioPharma, CTI Clinical Trial and AllStripes.

Company Details

Website: ceriumpharma.com
Email ID: *****@ceriumpharma.com
Phone Number: +1 **********

Key Metrics

Founded Year

2012

Location

Gaithersburg, United States

Stage

Series A

Total Funding

$11.9M in 4 rounds

Latest Funding Round

Series A, May 22, 2026, $*****

Ranked

5^th among 29 active competitors

Employee Count

5 as on Sep 30, 2026

Similar Companies

Zenas BioPharma & 30 more

View Cerium's full profile

Cerium is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Cerium Pharmaceuticals, Inc. CIN: 45-4872095 , United States, Active	Dec 31, 2011	-	-	-

Cerium has raised a total funding of $11.9M over 4 rounds. Its first funding round was on Jun 27, 2016.

Here is the list of recent funding rounds of Cerium:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 22, 2026	4364723	Series A	3455902	1622369	7734407	3341370
Jul 30, 2021	1899213	Series A	1234754	7478449	4297303	2356888
May 25, 2021	3021748	Conventional Debt	8934558	5192644	6077516	9084598

Access funding benchmarks and valuations. Sign up today!

View details of Cerium's funding rounds and investors

The founders of Cerium is Gregg Lapointe. Gregg Lapointe is the CEO of Cerium.

Here are the details of Cerium's key team members:

Gregg Lapointe: Co-Founder & CEO of Cerium.
Contact Info: 1 email address

View details of Cerium's Founder profiles and Board Members

Cerium's employee count trend

Cerium has 5 employees as of Sep 26. Here is Cerium's employee count trend over the years:

Uncover Cerium's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cerium include Zenas BioPharma, CTI Clinical Trial and AllStripes. Here is the list of Top 10 competitors of Cerium, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Zenas BioPharma 2020, Fort Myers (United States), Public	Provider of clinical development services for autoimmune and rare diseases	$318M	Norwest, Enavate Sciences & 19 others	67/100
2nd	CTI Clinical Trial 1999, Cincinnati (United States), Unfunded	Clinical research organization providing comprehensive services for drug and device development	-	-	52/100
3rd	AllStripes 2017, San Francisco (United States), Acquired	Provider of information to patients and communities with the medical data for rare diseases	$67M	Lux Capital, Spark Capital & 16 others	48/100
4th	Prime Global 1997, London (United Kingdom), Late Stage	Provider of medical communication solutions	-	LLCP, HSBC & 1 others	47/100
5th	Cerium 2012, Gaithersburg (United States), Series A	CRO focusing on developing and commercialising of drugs for the treatment of orphan diseases	$11.9M	-	42/100
6th	Agility Clinical 2012, Carlsbad (United States), Acquired	CRO with a special focus on orphan drug development	$390K	-	40/100
7th	RDMD 2017, San Francisco (United States), Deadpooled	Provider of patient-centered clinical research platform and services for rare disease drug development	-	-	39/100
8th	Neurenati 2020, Montreal (Canada), Seed	Biotech company focused on developing therapies for rare diseases, with a current focus on Hirschsprung disease	$2.9M	Invest Quebec	38/100
9th	Oddifact France, Unfunded	Developer of AI-driven platform identifying and licensing orphan drug designations.	-	-	35/100
10th	Elpida Therapeutics 2023, Encino (United States), Unfunded	Biotechnology company focused on developing gene therapies for rare and ultra-rare diseases	-	-	35/100